Weiguang Biology: 2026 Semi-annual Results Forecast
Securities code: 002880 Securities abbreviation: Weiguang Biology Announcement number: 2026-033
Shenzhen Weiguang Biological Products Co., Ltd.
2026 Semi-annual Results Forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Performance forecast for this period
Performance forecast period: January 1, 2026 to June 30, 2026
Expected operating results:
Turn losses into profits Increase in the same direction Decline in the same direction
Items This reporting period The same period last year
Attributable to listed company shares
Profit: 43.06 million yuan-53.82 million yuan
Profitable net profit
Decrease compared with the same period last year: 60%-50%
107.6463 million yuan
Deduction of non-recurring gains and losses
Profit: 42.52 million yuan-53.15 million yuan
net profit after profit
Decrease compared with the same period last year: 60%-50%
Earnings of RMB 106.3037 million Basic earnings per share Earnings: RMB 0.1898/share - RMB 0.2373/share
0.4746 yuan/share
2. Communication with the accounting firm
The financial data related to this performance forecast have not been audited by certified public accountants.
3. Explanation of reasons for performance changes
Impact of tax policy adjustment: Affected by the 2026 Document No. 10 "Announcement of the Ministry of Finance and the State Administration of Taxation on the Transition of Preferential Value-Added Tax Policies after the Implementation of the Value-Added Tax Law", in addition to rare disease drugs, the company's other blood product business has changed from a simple 3% tax to a 13% general tax, resulting in pressure on the company's revenue and profits.
Impact of market environment: Due to intensified market competition, the company's sales of blood products have declined to a certain extent.
4. Risk warning
This performance forecast is the result of preliminary calculations by the company's financial department and has not been audited by an audit agency. The specific financial data is subject to the "2026 Semi-Annual Report" disclosed by the company. Investors are kindly requested to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Shenzhen Weiguang Biological Products Co., Ltd.
July 15, 2026